Redcare Pharmacy Faces Dual Challenges as Key Payment and New Rival Loom

Redcare Pharmacy NL0012044747

Redcare Pharmacy is entering 2026 under significant strain. The MDAX-listed company’s shares have lost approximately half their value over the past twelve months, trading perilously close to the €65 mark. Management is confronting pressure from two sides: a substantial payment due in January and an aggressive new competitor targeting its core business.

Perhaps the more critical long-term threat is a rapidly shifting competitive landscape. On December 16, dm-drogerie markt launched its “dm-med” platform, launching a direct assault on the over-the-counter medication market. The company is strategically shipping orders from the Czech Republic, a move that puts pressure on Redcare Pharmacy’s cost structure.